From Elon Musk to several Hollywood celebrities, the weight loss wonder drug, semaglutide, is taking the world by storm. What was an unintended consequence of a diabetes control med, the emergence of significant weight loss has raised the expectation of the wonder drug becoming a $100 bn opportunity by 2030. While the drug’s innovator Novo Nordisk launched its oral version in India last year, Dr. Reddys Laboratories has now got approval to carry out bioequivalence studies of injectable semaglutide. So, what does this mean for India that has a huge disease burden of diabetes and obesity? Is the hype around the drug all worth it? Are there any side effects? Is it affordable? And who should be taking it? Host Kiran Somvanshi tries to understand from Dr. Ambrish Mithal, Chairman & Head - Endocrinology & Diabetes - Max Healthcare, and Nithya Balasubramanian, Director - AB Bernstein. Listen to the latest episode of The Morning Brief podcast!
Disclaimer: The analyst interviewed has a financial interest in Cipla and Lupin.
Credits: Ozempic Commercial and Jimmy Kimmel Live
If you like this episode, check out other interesting episodes on Watch Before You Eat, Cipla Saga - Did The Doctor Prescribe A Sale?, Cheeni Kum: The Bitter Truth of Aspartame and more!
You can follow our host Kiran Somvanshi on her social media: Twitter & Linkedin
Catch the latest episode of ‘The Morning Brief’ on ET Play, The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Google Podcasts.
See omnystudio.com/listener for privacy information.
